<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2448-8909</journal-id>
<journal-title><![CDATA[Medicina crítica (Colegio Mexicano de Medicina Crítica)]]></journal-title>
<abbrev-journal-title><![CDATA[Med. crít. (Col. Mex. Med. Crít.)]]></abbrev-journal-title>
<issn>2448-8909</issn>
<publisher>
<publisher-name><![CDATA[Colegio Mexicano de Medicina Crítica A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2448-89092021000300136</article-id>
<article-id pub-id-type="doi">10.35366/100002</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Uso de ácido ascórbico en pacientes con traumatismo craneoencefálico severo y su impacto en el tiempo de estancia en la Unidad de Cuidados Intensivos adultos]]></article-title>
<article-title xml:lang="en"><![CDATA[Ascorbic acid use in severe traumatic brain injury patients and its impact on the adult Intensive Care Unit stance]]></article-title>
<article-title xml:lang="pt"><![CDATA[Uso de ácido ascórbico em pacientes com traumatismo cranioencefálico grave e seu impacto no tempo de permanência na unidade de terapia intensiva para adultos]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Macías Limón]]></surname>
<given-names><![CDATA[Juan Diego de Jesús]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández Plata]]></surname>
<given-names><![CDATA[Alma Erika]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bravo Santibáñez]]></surname>
<given-names><![CDATA[Edgar]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández]]></surname>
<given-names><![CDATA[Martha Alicia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Centro Médico Nacional Bajío No. 1 Unidad Médica de Alta Especialidad]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2021</year>
</pub-date>
<volume>35</volume>
<numero>3</numero>
<fpage>136</fpage>
<lpage>143</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2448-89092021000300136&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2448-89092021000300136&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2448-89092021000300136&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción:  El traumatismo craneoencefálico (TCE) es la principal causa de muerte y discapacidad en adultos jóvenes alrededor del mundo. La lesión secundaria se desarrolla con liberación de radicales libres de oxígeno. Además de su potente acción como reductor de radicales libres, el ácido ascórbico estabiliza el endotelio y promueve la integridad de la barrera hematoencefálica (BHE).  Objetivo:  Determinar la utilidad del ácido ascórbico en pacientes con TCE severo y su impacto en el tiempo de estancia hospitalaria en la Unidad de Cuidados Intensivos adultos (UCI).  Material y métodos:  Ensayo clínico aleatorizado, abierto en UCI del Centro Médico Nacional del Bajío UMAE No. 1, León, Guanajuato, México, de abril 2020 a julio 2020. Ingresaron 24 pacientes (12 grupo experimental y 12 controles) mediante muestreo probabilístico con TCE severo en mayores de 18 años. Administración de ácido ascórbico un gramo cada seis horas intravenoso. Se correlacionaron administración de ácido ascórbico con tiempo de estancia hospitalaria en UCI y hospitalización, mortalidad y escalas neurológicas. Análisis de resultados SPSS versión 21.  Resultados:  Se incluyeron 24 pacientes, medias de edad 26 y 49 años grupo experimental y control respectivamente (p = 0.004). Promedio de la Escala de Coma de Glasgow al momento del ingreso fue 7 y 6.7 puntos respectivamente (p = 0.378). Estancia en la UCI con 7 y 3.71 días (p = 0.001), estancia hospitalaria 12.5 y 5.85 días respectivamente (p = 0.001). Al egreso, la escala de Glasgow 3.50 y 3.57 puntos respectivamente (p = 0.630). Mortalidad a 28 días de 1 y 3 casos respectivamente (p = 0.59); el análisis de supervivencia reflejó mayor supervivencia para el grupo experimental (p = 0.010).  Conclusión:  El uso de ácido ascórbico en TCE severo impactó de manera negativa en la estancia en UCI, así como tiempo de hospitalización. El análisis de supervivencia mostró menor mortalidad a 28 días para el grupo experimental respecto al control.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Introduction:  Traumatic brain injury (TBI) is the leading cause of death and disability in young adults around the world. The secondary lesion develops with the release of oxygen free radicals. In addition to its powerful action as a free radical scavenger, ascorbic acid stabilizes the endothelium and promotes the integrity of the blood-brain barrier (BBB).  Objective:  To determine the usefulness of ascorbic acid in patients with severe TBI and its impact on the length of hospital stay in the Adult Intensive Care Unit (ICU).  Material and methods:  Randomized clinical trial, open in the ICU of the Centro Médico Nacional del Bajío UMAE No. 1, León, Guanajuato, Mexico, from April 2020 to July 2020. 24 patients (12 experimental group and 12 controls) were admitted by probabilistic sampling with Severe TBI in people over 18 years of age. Administration of ascorbic acid one gram every six hours intravenously. Ascorbic acid administration was correlated with length of stay in ICU and hospitalization, mortality and neurological scales. Analysis of SPSS version 21 results.  Results:  24 patients were included, mean ages 26 and 49 years, experimental and control group respectively (p = 0.004). Average of the Glasgow Coma Scale at the time of admission was 7 and 6.7 points respectively (p = 0.378). Stay in the ICU with 7 and 3.71 days (p = 0.001), hospital stay 12.5 and 5.85 days respectively (p = 0.001). At discharge, the Glasgow scale resulted in 3.50 and 3.57 points respectively (p = 0.630). 28-day mortality of 1 and 3 cases respectively (p = 0.59); the survival analysis reflected higher survival for the experimental group (p = 0.010).  Conclusion:  The use of ascorbic acid in severe TBI had a negative impact on the ICU stay, as well as the length of hospitalization. Survival analysis showed lower mortality at 28 days for the experimental group compared to the control.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo:  Introdução:  O traumatismo cerebral (TCE) é a principal causa de morte e incapacidade em jovens adultos em todo o mundo. A lesão secundária se desenvolve com a liberação de radicais livres de oxigênio. Além de sua poderosa ação como redutor de radicais livres, o ácido ascórbico estabiliza o endotélio e promove a integridade da barreira hematoencefálica (BHE).  Objetivo:  Determinar a utilidade do ácido ascórbico em doentes com TCE grave e o seu impacto no tempo de hospitalização na Unidade de Cuidados Intensivos (UTI) de adultos.  Material e métodos:  Ensaio clínico aleatório, aberto na UTI do Centro Médico Nacional del Bajío UMAE No. 1, León, Guanajuato, México, de Abril de 2020 a Julho de 2020. Vinte e quatro pacientes (12 grupos experimentais e 12 controlos) foram admitidos por amostragem probabilística com TCE grave em pacientes com mais de 18 anos de idade. Administração de ácido ascórbico uma grama a cada seis horas por via intravenosa. Correlacionou-se a administração do ácido ascórbico com o tempo de estadia hospitalar na UTI e a hospitalização, mortalidade e escalas neurológicas. Análise de resultados SPSS versão 21.  Resultados:  24 pacientes foram incluídos, idade média de 26 e 49 anos, respectivamente, grupo experimental e grupo de controle (p = 0.004). A Escala Média de Coma de Glasgow na admissão foi de 7 e 6.7 pontos respectivamente (p = 0.378). A estadia na UCI foi de 7 e 3.71 dias (p = 0.001), a estadia hospitalar foi de 12.5 e 5.85 dias, respectivamente (p = 0.001). Na alta, a escala Glasgow pontua 3.50 e 3.57, respectivamente (p = 0.630). Mortalidade a 28 dias de 1 e 3 casos respectivamente (p = 0.59); a análise de sobrevivência reflectiu uma maior sobrevivência para o grupo experimental (p = 0.010).  Conclusão:  O uso de ácido ascórbico em TCE grave teve impacto negativo na permanência na UTI, bem como no tempo de internação. A análise de sobrevivência mostrou menor mortalidade em 28 dias para o grupo experimental em comparação com o controle.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Traumatismo craneoencefálico]]></kwd>
<kwd lng="es"><![CDATA[ácido ascórbico]]></kwd>
<kwd lng="es"><![CDATA[estancia en Unidad de Cuidados Intensivos]]></kwd>
<kwd lng="es"><![CDATA[mortalidad]]></kwd>
<kwd lng="en"><![CDATA[Head trauma]]></kwd>
<kwd lng="en"><![CDATA[ascorbic acid]]></kwd>
<kwd lng="en"><![CDATA[stay in Intensive Care Unit]]></kwd>
<kwd lng="en"><![CDATA[mortality]]></kwd>
<kwd lng="pt"><![CDATA[Traumatismo craniano]]></kwd>
<kwd lng="pt"><![CDATA[ácido ascórbico]]></kwd>
<kwd lng="pt"><![CDATA[permanência na Unidade de Terapia Intensiva]]></kwd>
<kwd lng="pt"><![CDATA[mortalidade]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="">
<collab>Centers for Disease Control and Prevention</collab>
<source><![CDATA[Surveillance report of traumatic brain injury-related emergency department visits, hospitalizations, and deaths]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Raúl]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[Martín]]></surname>
<given-names><![CDATA[MMJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trauma craneoencefálico]]></article-title>
<source><![CDATA[Rev Mex de Anestesiología]]></source>
<year>2015</year>
<volume>38</volume>
<page-range>S433-S4</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<source><![CDATA[Guía de Práctica Clínica GPC Atención inicial de pacientes con traumatismo craneoencefálico grave en urgencias]]></source>
<year>2018</year>
<publisher-loc><![CDATA[México ]]></publisher-loc>
<publisher-name><![CDATA[Instituto Mexicano del Seguro Social]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Timmons]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
</person-group>
<collab>Springer</collab>
<source><![CDATA[Controversies in severe traumatic brain injury management]]></source>
<year>2018</year>
<page-range>285</page-range><publisher-name><![CDATA[Springer: Springer]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Taylor]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Bell]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Breiding]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[LK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Traumatic brain injury-related emergency department visits, hospitalizations, and deaths-United States, 2007 and 2013]]></article-title>
<source><![CDATA[MMWR Surveill Summ]]></source>
<year>2017</year>
<volume>66</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1-18</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leichtle]]></surname>
<given-names><![CDATA[SW]]></given-names>
</name>
<name>
<surname><![CDATA[Sarma]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Strein]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Yajnik]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Rivet]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Sima]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[High-dose intravenous ascorbic acid: ready for prime time in traumatic brain injury?]]></article-title>
<source><![CDATA[Neurocrit Care]]></source>
<year>2020</year>
<volume>32</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>333-9</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="">
<collab>SINAVE</collab>
<source><![CDATA[Aspectos clínicos y epidemiológicos del trauma craneoencefálico en México]]></source>
<year>2008</year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Teasdale]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Maas]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lecky]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Manley]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Stocchetti]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Murray]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Glasgow Coma scale at 40 years: standing the test of time]]></article-title>
<source><![CDATA[Lancet Neurol]]></source>
<year>2014</year>
<volume>13</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>844-54</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Munana-Rodríguez]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Elías]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Escala de coma de Glasgow: origen, análisis y uso apropiado]]></article-title>
<source><![CDATA[Enferm Univ]]></source>
<year>2014</year>
<volume>11</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>24-35</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carney]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Totten]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[O&#8217;Reilly]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ullman]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Hawryluk]]></surname>
<given-names><![CDATA[GWJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bell]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Guidelines for the management of severe traumatic brain injury]]></article-title>
<source><![CDATA[Neurosurgery]]></source>
<year>2017</year>
<volume>80</volume>
<numero>1</numero>
<edition>4</edition>
<issue>1</issue>
<page-range>6-15</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Picetti]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Rossi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Abu-Zidan]]></surname>
<given-names><![CDATA[FM]]></given-names>
</name>
<name>
<surname><![CDATA[Ansaloni]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Armonda]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Baiocchi]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[WSES consensus conference guidelines: monitoring and management of severe adult traumatic brain injury patients with polytrauma in the first 24 hours]]></article-title>
<source><![CDATA[World J Emerg Surg]]></source>
<year>2019</year>
<volume>14</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>53</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stocchetti]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Carbonara]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Citerio]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Ercole]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Skrifvars]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Smielewski]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Severe traumatic brain injury: targeted management in the intensive care unit]]></article-title>
<source><![CDATA[Lancet Neurol]]></source>
<year>2017</year>
<volume>16</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>452-64</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baratloo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Shokravi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Safari]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Aziz]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Predictive value of Glasgow coma score and full outline of unresponsiveness score on the outcome of multiple trauma patients]]></article-title>
<source><![CDATA[Arch Iran Med]]></source>
<year>2016</year>
<volume>19</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>215-20</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[AW]]></given-names>
</name>
<name>
<surname><![CDATA[Pretz]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
<name>
<surname><![CDATA[Bell]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
<name>
<surname><![CDATA[Hammond]]></surname>
<given-names><![CDATA[FM]]></given-names>
</name>
<name>
<surname><![CDATA[Arciniegas]]></surname>
<given-names><![CDATA[DB]]></given-names>
</name>
<name>
<surname><![CDATA[Bodien]]></surname>
<given-names><![CDATA[YG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Predictive utility of an adapted Marshall head CT classification scheme after traumatic brain injury]]></article-title>
<source><![CDATA[Brain Injury]]></source>
<year>2019</year>
<volume>33</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>610-7</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kinoshita]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Traumatic brain injury: pathophysiology for neurocritical care]]></article-title>
<source><![CDATA[J Intensive Care]]></source>
<year>2016</year>
<volume>4</volume>
<page-range>29</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Polidori]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Mecocci]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Frei]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Plasma vitamin C levels are decreased and correlated with brain damage in patients with intracranial hemorrhage or head trauma]]></article-title>
<source><![CDATA[Stroke]]></source>
<year>2001</year>
<volume>32</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>898-902</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Song]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[JY]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[JY]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dehydroascorbic acid attenuates ischemic brain edema and neurotoxicity in cerebral ischemia: an in vivo study]]></article-title>
<source><![CDATA[Exp Neurobiol]]></source>
<year>2015</year>
<volume>24</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>41-54</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ishaq]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Saidu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Bilbis]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Muhammad]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Jinjir]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Shehu]]></surname>
<given-names><![CDATA[BB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of &#945;-tocopherol and ascorbic acid in the severity and management of traumatic brain injury in albino rats]]></article-title>
<source><![CDATA[J Neurosci Rural Pract]]></source>
<year>2013</year>
<volume>4</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>292-7</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Winkler]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Minter]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Yue]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
<name>
<surname><![CDATA[Manley]]></surname>
<given-names><![CDATA[GT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cerebral edema in traumatic brain injury pathophysiology and prospective therapeutic targets]]></article-title>
<source><![CDATA[Neurosurg Clin N Am]]></source>
<year>2016</year>
<volume>27</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>473-88</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jain]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
</person-group>
<source><![CDATA[The handbook of neuroprotection]]></source>
<year>2019</year>
<edition>2</edition>
<page-range>865</page-range><publisher-name><![CDATA[Springer Nature: Humana Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Broderick]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Adeoye]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Elm]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evolution of the modified rankin scale and its use in future stroke trials]]></article-title>
<source><![CDATA[Stroke]]></source>
<year>2017</year>
<volume>48</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>2007-12</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McMillan]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ponsford]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Levin]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Teasdale]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Bond]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Glasgow outcome scale-40 years of application and refinement]]></article-title>
<source><![CDATA[Nat Rev Neurol]]></source>
<year>2016</year>
<volume>12</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>477-85</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yimcharoen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kittikunnathum]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Suknikorn]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Nak-on]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Yeethong]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Anthony]]></surname>
<given-names><![CDATA[TG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of ascorbic acid supplmentation on oxidative stress markers in healthy women following a single bout of exercise]]></article-title>
<source><![CDATA[J Int Soc Sports Nut]]></source>
<year>2019</year>
<volume>16</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>2</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fowler]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Syed]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Knowlson]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sculthorpe]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Farthing]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[DeWilde]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Phase I safety trial of intravenous ascorbic acid in patients with severe sepsis]]></article-title>
<source><![CDATA[J Transl Med]]></source>
<year>2014</year>
<volume>12</volume>
<page-range>32</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[May]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vitamin C transport and its role in the central nervous system]]></article-title>
<source><![CDATA[Sub-cellular Biochem]]></source>
<year>2012</year>
<volume>56</volume>
<page-range>85-103</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Buehner]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pamplin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Studer]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Hughes]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[King]]></surname>
<given-names><![CDATA[BT]]></given-names>
</name>
<name>
<surname><![CDATA[Graybill]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oxalate nephropathy after continuous infusion of high-dose vitamin c as an adjunct to burn resuscitation]]></article-title>
<source><![CDATA[J Burn Care Res]]></source>
<year>2016</year>
<volume>37</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>e374-9</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nathens]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Neff]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Jurkovich]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Klotz]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Farver]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Ruzinski]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Randomized, prospective trial of antioxidant supplmentation in critically ill surgical patients]]></article-title>
<source><![CDATA[Ann Surg]]></source>
<year>2002</year>
<volume>236</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>814-22</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sanford]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Fisher]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Fowler]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Fowler]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Natarajan]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Attenuation of red blood cell storage lesions with vitamin C]]></article-title>
<source><![CDATA[Antioxidants]]></source>
<year>2017</year>
<volume>6</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>55</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Figueroa-Mendez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Rivas-Arancibia]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vitamin C in health and disease: its role in the metabolism of cells and redox state in the brain]]></article-title>
<source><![CDATA[Front Physiol]]></source>
<year>2015</year>
<volume>6</volume>
<page-range>397</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kelly]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Morrow]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Ning]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Koroshetz]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Lo]]></surname>
<given-names><![CDATA[EH]]></given-names>
</name>
<name>
<surname><![CDATA[Terry]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oxidative stress and matrix metalloproteinase-9 in acute ischemic stroke - The biomarker evaluation for antioxidant therapies in stroke (BEAT-stroke) study]]></article-title>
<source><![CDATA[Stroke]]></source>
<year>2008</year>
<volume>39</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>100-4</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Razmkon]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sadidi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sherafat-Kazemzadeh]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Mehrafshan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Jamali]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Malekpour]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Administration of vitamin C and vitamin E in severe head injury: a randomized double-blind controlled trial]]></article-title>
<source><![CDATA[Clin Neurosurg]]></source>
<year>2011</year>
<volume>58</volume>
<page-range>133-7</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
